Le Lézard
Classified in: Health
Subject: ACC

Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC Receive UL Inspection and Conformance Certifications


LANDING, New Jersey, Sept. 13, 2018 /PRNewswire/ -- Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC, (UET) are proud to announce they have attained 21 CFR 111:4-2-16 certification in accordance with the Retail Certification Program.  This means that their joint facility at 9 Lenel Rd. in Landing, NJ, was audited by UL Registrar, LLC, using an accredited certification process to determine that the organization is found in conformance with Good Manufacturing Practice (GMP) guidelines, 21 CFR 111:4-2016.

Orcas Naturals, Inc. and Unique Encapsulation Technology, LLC receive UL Inspection and Conformance Certifications

GMPs are guidelines that provide a system of processes, procedures, and documentation to assure a product has the identity, strength, composition, quality, and purity that appear on the product label. These GMP requirements are listed under FD&C Act section 520(f).

The UL Registrar LLC GMP Certification Program enables manufactures to become independently registered by UL to meet GMP requirements for the manufacturing, packaging, holding, and distribution of finished products, components, ingredients, and/or raw materials. "Conformance to the UL standard adds credence to our in-house QC laboratory protocols and vendor qualification measures, helping us demonstrate our commitment to public safety," says K G Rao, President of Orcas Naturals and UET.

The certification covers the Landing, NJ, location and includes the manufacturing, packaging, warehousing, and distribution of dietary supplements as raw materials as well as powders and liquid-filled capsules.

Orcas Naturals and UET created a strategic alliance that provides clients with one-stop service for turnkey ingredient sourcing, conventional and customized formulations, and unique filling technologies.

"The UL GMP certification for facility operation and management systems holds us accountable to our vision of delivering quality ingredients in state of the art capsules," notes Rao.."We fulfill a unique niche in our market, offering small batch sizes, delivering rapid turnaround times and leading with a strong team of quality professionals. As an industry authority, GMP status strengthens our customers' confidence in our mission to help them differentiate their final product in a competitive market."

For more information, contact:

Company contact:

Press Contact:

Orcas Naturals

NutriPR

Vijay Khadse

Liat Simha

Quality Director

Tel: +972-9-9742893

E-mail: [email protected]

E-mail: [email protected]

Website: www.orcasnaturals.com

Website: www.nutripr.com


Twitter: @LiatSimha

 

SOURCE Orcas Naturals, Inc.; Unique Encapsulation Technology


These press releases may also interest you

at 13:26
In a bid to foster excellence and innovation in the healthcare industry, the esteemed Dr. Vidal Sheen proudly announces the launch of The Dr. Vidal Sheen Grant for Healthcare Students. With a robust focus on academic prowess, compassionate care, and...

at 13:17
Rexall is proud to unveil its first Pharmacist Care Walk-In Clinic in Barrie, Ontario on Friday, April 19. Located at 353 Duckworth Street, the clinic will offer personalized care to the community while providing immediate pharmacist treatment for...

at 13:13
Caring for communities extends beyond life-changing work in operating rooms and physician offices. Hartford HealthCare leadership today highlighted its corporate responsibility to environmental, social and economic sustainability in announcing its...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:30
The American College of Physicians (ACP) today released an update of its 2017 guideline with clinical recommendations for the use of newer pharmacological treatments of adults with Type 2 diabetes. The clinical guideline is based on the best...

at 12:10
Pieris Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's...



News published on and distributed by: